DANTHRON

US Previously Marketed

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H8O4
Molecular Weight	240.2109
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=CC2=C1C(=O)C3=C(O)C=CC=C3C2=O

InChI

InChIKey=QBPFLULOKWLNNW-UHFFFAOYSA-N

InChI=1S/C14H8O4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16H

HIDE SMILES / InChI

Molecular Formula	C14H8O4
Molecular Weight	240.2109
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.sciencedirect.com/science/article/pii/B9780123864543012148
Curator's Comment: Description was created based on several sources, including https://ntp.niehs.nih.gov/ntp/roc/content/profiles/danthron.pdf

Danthron, a natural product, was originally extracted from the roots and rhizome of Polygonaceae plant. Danthron is an anthraquinone. Danthron has been widely administrated as a laxative since the 1900s. In the United States, danthron has been forbidden to continual use as laxative because it is considered to be a carcinogen. In the UK, it is not marketed alone but in combination with poloxamer 188 as co-danthramer and with docusate as co-danthrusate; in the UK, its use is strictly restricted to the elderly and to the terminally ill of all ages because of concerns about carcinogenicity and hepatotoxicity. It has only a limited role in the treatment of constipation.

Approval Year

Targets

Primary Target	Pharmacology	Potency
AMP-activated protein kinase, AMPK 17 Target ID: CHEMBL2096907 Sources: http://www.nature.com/aps/journal/v34/n8/pdf/aps201339a.pdf	Activator 1430
DNA topoisomerase II alpha 37 Target ID: CHEMBL3586 Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=9630566	Inhibitor 8297	14.0 µM [IC50]
Retinoid X receptor alpha 11 Target ID: CHEMBL2061 Sources: http://www.jbc.org/content/286/3/1868.full.pdf+html	Antagonist 2778	7.5 µM [Kd]
Apoptosis 155 Target ID: map04210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/19784869	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Constipation in terminally ill patients 1 Sources: http://www.drugs.com/uk/pdf/leaflet/676118.pdf	Curative		Withdrawn	Normax Approved Use Normax 50mg/60mg Capsules should only be used to relieve constipation in patients who are seriously ill. Normax 50mg/60mg Capsules work by encouraging normal bowel movements.

Doses

Dose	Population	Adverse events
25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Co-administed with:: poloxalkol(200 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/2594597/	unhealthy, 18 years n = 1 Health Status: unhealthy Condition: constipation Age Group: 18 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2594597/	Other AEs: Leiomyosarcoma... Other AEs: Leiomyosarcoma Sources: https://pubmed.ncbi.nlm.nih.gov/2594597/
25 mg 1 times / day single, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: single Dose: 25 mg, 1 times / day Co-administed with:: poloxalkol(200 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/638688/	unhealthy, 51 years n = 1 Health Status: unhealthy Condition: psychiatric ailments Age Group: 51 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/638688/	Other AEs: Skin discoloration... Other AEs: Skin discoloration Sources: https://pubmed.ncbi.nlm.nih.gov/638688/
25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Co-administed with:: poloxalkol(200 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/	unhealthy, 65 to 88 years n = 20 Health Status: unhealthy Condition: constipation Age Group: 65 to 88 years Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/	Other AEs: Diarrhoea, Faecal incontinence... Other AEs: Diarrhoea (35%) Faecal incontinence (55%) Rash (15%) Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: docusate sodium(60 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/1451505/	unhealthy, 80 and 69 years n = 2 Health Status: unhealthy Condition: constipation Age Group: 80 and 69 years Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/1451505/	Disc. AE: Contact dermatitis... AEs leading to discontinuation/dose reduction: Contact dermatitis Sources: https://pubmed.ncbi.nlm.nih.gov/1451505/

AEs

AE	Significance	Dose	Population
Leiomyosarcoma		25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Co-administed with:: poloxalkol(200 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/2594597/	unhealthy, 18 years n = 1 Health Status: unhealthy Condition: constipation Age Group: 18 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2594597/
Skin discoloration		25 mg 1 times / day single, oral Studied dose Dose: 25 mg, 1 times / day Route: oral Route: single Dose: 25 mg, 1 times / day Co-administed with:: poloxalkol(200 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/638688/	unhealthy, 51 years n = 1 Health Status: unhealthy Condition: psychiatric ailments Age Group: 51 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/638688/
Rash	15%	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Co-administed with:: poloxalkol(200 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/	unhealthy, 65 to 88 years n = 20 Health Status: unhealthy Condition: constipation Age Group: 65 to 88 years Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/
Diarrhoea	35%	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Co-administed with:: poloxalkol(200 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/	unhealthy, 65 to 88 years n = 20 Health Status: unhealthy Condition: constipation Age Group: 65 to 88 years Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/
Faecal incontinence	55%	25 mg 1 times / day multiple, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: multiple Dose: 25 mg, 1 times / day Co-administed with:: poloxalkol(200 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/	unhealthy, 65 to 88 years n = 20 Health Status: unhealthy Condition: constipation Age Group: 65 to 88 years Sex: M+F Population Size: 20 Sources: https://pubmed.ncbi.nlm.nih.gov/5371464/
Contact dermatitis	Disc. AE	50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Co-administed with:: docusate sodium(60 mg; oral; 1/day) Sources: https://pubmed.ncbi.nlm.nih.gov/1451505/	unhealthy, 80 and 69 years n = 2 Health Status: unhealthy Condition: constipation Age Group: 80 and 69 years Sex: F Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/1451505/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1461	UGT1A1 418 UGT1A6 307 UGT1A7 236 UGT1A9 380 UGT1A10 291

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1650	inhibitor 3277 Sources: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1747-0285.2011.01089.x	no

Drug as victim

Target	Modality	Activity
UGT1A1 418	substrate 3367 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxMjg3NjE3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUzNDE4In19, https://www.annualreviews.org/doi/10.1146/annurev.pharmtox.40.1.581	no
UGT1A6 307	substrate 3367 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMzE2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUzNDE4In19, https://www.annualreviews.org/doi/10.1146/annurev.pharmtox.40.1.581	no
UGT1A9 380	substrate 3367 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMzE5IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUzNDE4In19, https://www.annualreviews.org/doi/10.1146/annurev.pharmtox.40.1.581	no
UGT1A10 291	substrate 3367 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMzIwIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUzNDE4In19, https://www.annualreviews.org/doi/10.1146/annurev.pharmtox.40.1.581	yes
UGT1A7 236	substrate 3367 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMzE3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDUzNDE4In19, https://www.annualreviews.org/doi/10.1146/annurev.pharmtox.40.1.581	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY455324	https://www.001chemical.com/chem/117-10-2
3B Scientific (Wuhan) Corp	3B1-00529	http://www.3bsc.com/index/pro_info.php?id=20741
AA Blocks	AA000DF4	https://www.aablocks.com/goods/Goods/detail?id=AA000DF4
AEchem Scientific Corp., USA	AE038910	http://www.aechemsc.com/info_products/AE038910.php
AHH Chemical co.,ltd	NP-0345	http://www.ahhchemical.com/product/NP-0345.html
AK Scientific, Inc. (AKSCI)	R229	http://www.aksci.com/item_detail.php?cat=R229
Aaron Chemicals	AR000E6W	http://www.aaronchem.com/117-10-2
AbMole Bioscience	M5549	http://www.abmole.com/products/danthron.html
Acadechem	ACDS-033112	http://www.acadechemical.com/product/107811
Accela ChemBio Inc	SY011288	http://www.accelachem.com/cn/search.html?keyword=SY011288&attname=GoodsCode
Achemica	ACMC-20mzuc	http://www.achemica.com/prodinfo/?id=227325
Achemo Scientific Limited	AC-23294	http://www.achemo.com/search/?Keyword=117-10-2
Acorn PharmaTech	ACN-035237	http://www.acornpharmatech.com/
Acros Organics	AC114830050	https://www.fishersci.com/shop/products/1-8-dihydroxyanthraquinone-90-95-acros-organics/AC114830050
Acros Organics	AC114831000	https://www.fishersci.com/shop/products/1-8-dihydroxyanthraquinone-90-95-acros-organics/AC114831000
Acros Organics	AC114835000	https://www.fishersci.com/shop/products/1-8-dihydroxyanthraquinone-90-95-acros-organics/AC114835000
Alfa Aesar	A12001	https://www.alfa.com/en/catalog/A12001/
Alfa Chemistry	AP117102	https://reagents.alfa-chemistry.com/product/danthrone-cas-117-10-2-2185.html
Alichem	19150111	http://www.alichem.com/en/products/117-10-2.html
Ambinter	Amb1349101	http://www.ambinter.com/reference/1349101
Angene	AGN-PC-0JK6EB	http://www.angenechemical.com/productshow/AGN-PC-0JK6EB.html
Anward	ANW-17004	http://www.anward.com/pro_result/3917
Ark Pharm	AK208660	http://www.arkpharminc.com/products/117-10-2.html
Ark Pharma Scientific Limited	N-1556	http://www.arkpharmtech.com/product/241897.html
Aronis	ARONIS23892	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=1164
AvaChem Scientific	4000	http://www.avachem.com/productSearch.asp?4000
BLD Pharm	BD55176	http://www.bldpharm.com/products/117-10-2.html
BOC Sciences	1246816-27-2	https://isotope.bocsci.com/product/1-8-dihydroxyanthraquinone-d6-cas-1246816-27-2-346722.html
BioChemPartner	BCP31079	http://www.biochempartner.com/117-10-2-BCP31079
BioCrick	BCN6048	http://www.biocrick.com/Dantron-BCN6048.html
BioSynth	W-108572	https://www.biosynth.com/en/products/chemical-intermediates/advanced-intermediates/products/W-108572.html
CSNpharm	CSN17102	https://www.csnpharm.com/products/1,8-dihydroxyanthraquinone.html
Chem Scene	CS-4392	http://www.chemscene.com/117-10-2.html
ChemFaces	CFN99271	http://www.chemfaces.com/natural/Dantron-CFN99271.html
ChemMol	49426487	http://www.chemmol.com/chemmol/49426487.html
ChemMol	80101169	http://www.chemmol.com/chemmol/80101169.html
Chemspace	CSSB00016997201	https://chem-space.com/CSSB00016997201
Clearsynth	CS-T-89385	https://www.clearsynth.com/en/CST89385.html
DC Chemicals	DCE-005	http://www.dcchemicals.com//product_show-1_8_Dihydroxyanthraquinone.html
Finetech	FT-0624445	http://www.finetechnology-ind.com/prod/detail/pub/117-10-2.html
FondChemical	FDB-2803	http://www.fondchemical.com/cpshow_cid_8_pid_2090.html
Glentham Life Sciences	GK4516	http://www.glentham.com/products/product/GK4516/
Hairui	HR135029	http://www.hairuichem.com/en/product/117-10-2.html
LGC Standards	DRE-C11961000	https://www.lgcstandards.com/US/en/p/DRE-C11961000
LGC Standards	LGCFOR0137.01	https://www.lgcstandards.com/US/en/p/LGCFOR0137.01
LGC Standards	MM0137.01	https://www.lgcstandards.com/US/en/p/MM0137.01
Lab Network	LN00159216	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00159216
Matrix Scientific	58300	https://www.matrixscientific.com/058300.html
MedChem Express	HY-B0923	https://www.medchemexpress.com/Danthron.html
Molcore	MC455324	https://www.molcore.com/product/117-10-2
MuseChem	I000607	https://www.musechem.com/product/I000607.html
Parchem	1364	http://www.parchem.com/chemical-supplier-distributor/1-8-Dihydroxy-Anthraquinone-002712.aspx
R&D Chemicals	417	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=7720
Renno Tech	RP28420	http://www.rennotech.com/product_show.asp?id=34036
Sigma-Aldrich	D108103_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/d108103?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	V900576_VETEC	https://www.sigmaaldrich.com/catalog/product/vetec/v900576?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S017455	http://www.sinfoobiotech.com/product/1020853
Smolecule	S525002	http://www.smolecule.com/products/s525002
Smolecule	S748642	https://www.smolecule.com/products/s748642
TCI (Tokyo Chemical Industry)	D0563	http://www.tcichemicals.com/eshop/en/us/commodity/D0563/index.html
THE BioTek	bt-264432	https://www.thebiotek.com/product/inhibitors/bt-264432
VladaChem	VL266649-100G	https://www.vladachem.com/product.php?products=117-10-2
abcr GmbH	AB109119	http://www.abcr.com/shop/en/AB109119
eNovation Chemicals	D409459	http://www.enovationchem.com/productDetails.asp?productID=D409459
iChemical	EBD217295	http://www.ichemical.com/products/117-10-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-5800615690	https://mcule.com/MCULE-5800615690/

PubMed

Title	Date	PubMed
Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus.	1992 Jan	1310583
Inhibitors of human immunodeficiency virus integrase.	1993 Mar 15	8460151
Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules.	1996 Sep 3	8790401
In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus.	2001 Mar	11428243
Antimutagenic effects of black tea (World Blend) and its two active polyphenols theaflavins and thearubigins in Salmonella assays.	2002 Nov	12410547
Bryoanthrathiophene, a new antiangiogenic constituent from the bryozoan Watersipora subtorquata (d'Orbigny, 1852).	2002 Sep	12350162
Emodin isolated from Cassia obtusifolia (Leguminosae) seed shows larvicidal activity against three mosquito species.	2003 Dec 17	14664519
Circular dichroism imaging microscopy: application to enantiomorphous twinning in biaxial crystals of 1,8-dihydroxyanthraquinone.	2003 Dec 3	14640658
Methotrexate for ankylosing spondylitis.	2004	15266537
Oxoazabenzo[de]anthracenes conjugated to amino acids: synthesis and evaluation as DNA-binding antitumor agents.	2005 Jul-Aug	16029036
Interaction of anthracene and its oxidative derivatives with human serum albumin.	2006	16404478
Defensive components in insect eggs: are anthraquinones produced during egg development?	2006 Sep	16835809
Initial in vitro screening approach to investigate the potential health and environmental hazards of Enviroxtrade mark - a nanoparticulate cerium oxide diesel fuel additive.	2007 Dec 5	18053256
Reactivity of aromatic amines with triplet 1,8-dihydroxyanthraquinone: a laser flash photolysis study.	2007 Jan	16815083
Simultaneous determination and pharmacokinetic studies of aloe emodin and chrysophanol in rats after oral administration of Da-Cheng-Qi decoction by high-performance liquid chromatography.	2007 Jul	17370297
Antiprotozoal activity of Senna racemosa.	2007 Jun 13	17481835
Potential benefits of non-pharmacological therapies in fibromyalgia.	2008	19088863
Solvent effect on the physical quenching of singlet molecular oxygen by p-quinones.	2008 Apr	18385892
Towards reconciling structure and function in the nuclear pore complex.	2008 Feb	18228033
Is senna laxative use associated to cathartic colon, genotoxicity, or carcinogenicity?	2009	20107583
Aloe-emodin-induced DNA fragmentation in the mouse in vivo comet assay.	2009 Aug	19559101
Structure-activity relationships of anthraquinones on the suppression of DNA-binding activity of the aryl hydrocarbon receptor induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin.	2009 Mar	19269596
Danthron inhibits the migration and invasion of human brain glioblastoma multiforme cells through the inhibition of mRNA expression of focal adhesion kinase, Rho kinases-1 and metalloproteinase-9.	2009 Nov	19787217
A high-throughput approach for identification of novel general anesthetics.	2009 Sep 24	19777064
The coverage problem in video-based wireless sensor networks: a survey.	2010	22163651
Enzymatic reduction of complex redox dyes using NADH-dependent reductase from Bacillus subtilis coupled with cofactor regeneration.	2010 Jan	19662398
Danthron induces DNA damage and inhibits DNA repair gene expressions in GBM 8401 human brain glioblastoma multiforms cells.	2010 Jul	20369292

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose for adults is one to three capsules at bedtime. The usual dose for children aged 6-12 years is one capsule at bedtime. Normax 50mg/60mg Capsules are not recommended for use by children under 6 years of age. This product should be taken orally (by mouth). You must swallow the capsules whole with a drink of water. The capsules must not be crushed or chewed. Normax 50mg/60mg Capsules normally begin to work 8 hours after the dose is taken.

Route of Administration: Oral

In Vitro Use Guide

10 uM danthron reduces growth of B16-F10 melanoma by 83%

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:14:52 GMT 2023` Edited by `admin` on `Fri Dec 15 15:14:52 GMT 2023`
Record UNII	Z4XE6IBF3V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DANTHRON

Common Name

English

1,8-DIHYDROXYANTHRACENE-9,10-DIONE

Systematic Name

English

CHRYSAZIN

Common Name

English

DITHRANOL IMPURITY B [EP IMPURITY]

Common Name

English

NSC-38626

Code

English

DANTHRON [MI]

Common Name

English

Dantron [WHO-DD]

Common Name

English

DANTRON [MART.]

Common Name

English

NSC-646568

Code

English

DORBANE

Brand Name

English

dantron [INN]

Common Name

English

DANTHRON [HSDB]

Common Name

English

1,8-Dihydroxyanthraquinone

Systematic Name

English

DANTRON

Official Name

English

DANTRON [IARC]

Common Name

English

ISTIZIN

Brand Name

English

PILULES VINCHY N.F.

Brand Name

English

DANTHRON [VANDF]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C45177